Australian scientists at Monash University have leveraged artificial intelligence to design novel proteins that inhibit membrane transporters essential for antibiotic-resistant Escherichia coli. Published in Nature Communications, their work demonstrates de novo-designed proteins blocking hemoglobin pirate pathways that bacteria use for growth. This approach exemplifies AI's emerging role in antimicrobial drug development, targeting nutrient uptake pathways with promising nanomolar potency inhibitors.